Neumirna Therapeutics secures euro 20M in Series A financing

08/01/2025

Neumirna Therapeutics secures euro 20M in Series A financing Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round...

Saving Lives with Venture Capital

07/09/2024

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...

The VC summer dream – the Fund Returner

08/07/2024

The VC summer dream – the Fund ReturnerSunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

25/03/2024

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive...